Another possibility is that the gain of function of mutant PI3K can amplify low levels of HER2 signaling that remain after single-inhibitor treatment of HER2+ breast cancer [23], but the combination of dual HER2 inhibitor blockade may reduce this low level of signaling and thus inhibit even PIK3CA mutant cancers. The gene discussed is PIK3CA; the disease is cancer.